. . World News – CA – Easy win of 1. 3% in October for industrial goods

besieged U. . S.. . The labor market is absorbing a new wave of unemployed. Last week there were 778. 000 new jobless claims submitted.

WASHINGTON – Orders to U. . S.. . Large-ticket industrial goods factories saw modest growth in October, but much of the strength came from a sharp surge in military equipment orders.

Orders for durable goods with a shelf life of at least three years rose better than expected 1. 3% in October and that gain followed an upward revised 2. 1% increase in September.

A category that has business investment plans increased by 0. 7% in October after a 1st. 9% increase in September.

October strength was mainly driven by the volatile defense contracts category, with military aircraft demand rising 79. 1%.

Orders for commercial aircraft, hit by the sharp drop in air traffic due to the coronavirus, rose by 38. 8%, but that comes after months of weakness. Economists are confident that demand for aircraft will continue to rise as Boeing finally receives safety clearances for its 737 Max, which was grounded after two fatal crashes.

Overall, the transport orders increased modestly by 1. 2% as the sector was held back by a 3. 2% fewer orders for vehicles and parts.

Economists believe that U. . S.. . Factories are facing significant headwinds, including a sharp spike in coronavirus cases that could slow demand in the coming months.

« Manufacturing remains exposed to severe virus cases that could disrupt supply chains, weigh on demand and slow the pace of future recovery, » said Rubeela Farooqi, chief executive U.. . S.. . Economist at High Frequency Economics.

Wages will be frozen for much of the public sector, but low-wage and NHS workers will be increased.

Amaravati (Andhra Pradesh) [India], 25. November (ANI): Andhra Pradesh has reported six deaths and 831 new cases of COVID-19 in the past 24 hours, according to a media bulletin published by the state-run COVID Andhra Pradesh -19 knot officer, on Wednesday.

Chancellor Rishi Sunak exposed the damage the coronavirus crisis had done to the nation’s finances.

The Chancellor was informed that his decision to reduce aid was « 100. 000 preventable deaths « – mostly in children.

Melissa McCarthy Mines laugh at AI contemplating the destruction of humanity in HBO Max’s « Superintelligence ». « She checked into Elon Musk’s lunch first.

The report « Off-Highway Vehicle Telematics Market Report – A Global and Regional Analysis: Focus On Device Types And Their Applications, Component Types, Solution Types, And Countries – Analysis And Forecast, 2019-2030 » has been added to ResearchAndMarkets. com offer.

Save on Black Friday 2020 sale on Apple Mac Pro and Mini deals, including 2019 Mac Pro deals. Here is our list of the latest Mac Pro and Mini Black Friday deals with the best savings on highly rated Apple computers and more. Links to the latest offers are listed below. Best Apple Mac Deals: * Save up to $ 50 on Apple Mac Mini – Click the link for the latest, live deals on Mac Pro computers on Amazon. * Save on the latest Mac Pro & Mac Mini Desktops from Apple on Amazon – click link for the latest prices on Apple computers such as Mac Pro 2019 and Mac Mini * Save on Apple Mac Pro & Mac Mini Desktops at B&H Photo Video – Check Live Pricing for Mac Pro (2019 Model) and Other Top-Rated Apple ComputersBest Apple iMac Deals: * Save On New Apple iMacs On Amazon – At 21. 5-inch & 27-inch with 4K and 5K Retina Displays * Save up to $ 90 on the Apple iMac Pro 27-inch on Amazon – Click the link for the latest iMac & pricing Get iMac Pro computers with Retina 5K displays * Save up to $ 150 on Apple iMac, Mac Pro & Mac Mini Desktops on B&H Photo Video * Save up to $ 445 on Apple iMac & iMac Pro (21). 5-inch & 27-inch) on Amazon – Click the link for the latest prices. 2019 iMac & iMac Pro Computer with Retina 5K Displays Need more offers? We recommend checking out Walmart’s Black Friday deals on Days Sale and Amazon Black Friday deals to compare more active savings. Deal Stripe earns commissions from purchases made through the links provided. About Deal Stripe: Deal Stripe shares e-commerce and sales news. As an Amazon Associate and Affiliate, Deal Stripe makes qualifying purchases. Contact: Andy Mathews (andy @ nicenetwork. com)

Compare all top Apple Watch deals for Black Friday, including savings on Apple Watch SE and & 6 Series 3, 4, 5

Growing value of stem cells in medicine creating $ 2. 4 Billion Chances for Induced Pluripotent Stem Cells (iPSC). The global induced pluripotent stem cell (iPSC) market is expected to reach $ 2. New York, Nov. . 25, 2020 (GLOBE NEWSWIRE) – Report linker. com Announces Publication of Global Induced Pluripotent Stem Cell (iPSC) Industry Report – https: // www. reportlinker. com / p05798831 /? utm_source = 4 billion. GNW by 2027, followed by a COVID-19 CAGR of 6. 6% in the analysis period 2020 to 2027. Stem cells are undifferentiated cells that have the ability to divide and differentiate into specialized cells in the body. Stem cells act as a repair system and replenish adult tissues, thereby maintaining the turnover of regenerative organs such as blood and skin. In organs such as bone marrow, stem cells often make replacement cells to repair the worn out tissue. These cells can react to signals from the body and go through a certain development path in order to differentiate into a certain cell type. Due to their regenerative properties, stem cells are being researched for therapeutic applications in diabetes, cardiovascular diseases, neurodegenerative diseases, cancer, autoimmune diseases and spinal cord defects. Stem cell research is an exciting field in which new sources of stem cells and new methods for their acquisition and harvest are continuously being discovered. Lately, adult stem cells have gained a lion’s share of stem cell space due to the fact that they require less expensive clinical trials compared to other stem cell variants such as the embryonic stem and have fewer regulatory norms and ethical issues to meet. Researchers around the world have focused their research on developing stem cell therapies for adults to fight a wide variety of diseases, ranging from diabetes to heart disease. In fact, adult stem cells are the only stem cells approved for use in transplants to treat diseases such as cancer. Interestingly, iPSCS offers an alternative step forward in the commercialization of stem cell therapies and regenerative medicine as embryonic stem cell drug development is challenged in a growing debate about ethics and regulation of this research. Embryonic stem cell research continues to be embroiled in ethical, religious, and political controversies in various countries around the world. Induced pluripotent stem cells (iPSs), which are reprogrammed to mimic the embryonic stem cell-like state and allow the expression of genes and human cells needed for therapeutic purposes, offer an attractive alternative for advancing the goals of stem cell research. These cells were developed in 2006 and developed the following year. They are made by converting somatic cells into PSCs through the introduction of certain genes such as Myc, Klf4, Oct3 / 4 and Sox2. Pluripotent stem cells have enormous potential in regenerative medicine. Because of their ability to reproduce indefinitely and develop into desirable cell types such as heart, liver, neuron, and pancreatic cells, iPSCs provide a source of new cells that can replace lost or damaged cells. For example, iPSCs can be converted to beta islet cells, blood cells or neuronal cells for the treatment of diabetes, leukemia or. neurological disorders are developed. Parkinson’s, Alzheimer’s & Spinal Cord Injuries are major neurological disorders that are expected to benefit from iPS research. The dramatic increase in cancer cases worldwide and the need for novel cancer therapies will emerge as major drivers for the growth of iPSCs. The interest in cancer research is increasing due to new hopes for a direct reprogramming of cancer cells with a forced expression of pluripotency factors and the resulting dedifferentiation of transformed cancer cells. The ongoing pandemic is also opening up new opportunities for human-induced pluripotent stem cells (hiPSCs) by providing researchers with a reliable model studying how the coronavirus affects various cells in the human body, indirectly or directly. Made from a small sample of blood or skin cells, HiPSCs are robust stem cells that can be developed into any cell type and then infected with the coronavirus in order to analyze disease prognosis and the resulting effects. Through the use of hiPSCs, researchers have found that cardiomyocytes (heart muscle cells) and blood vessels derived from stem cells are directly exposed to COVID-19 infection. Scientists identified that a significant proportion of the stem cell-derived cardiomyocytes stopped beating and leaked within 3 days of being infected with coronavirus. Researchers can use the infected cardiomyocytes to search for potential drug candidates that can restore their function and improve their survival. and also to identify new antiviral drugs that may limit coronavirus replication in the heart, reduce heart injuries, and limit disease prognosis. Researchers can also use the infected cardiomyocytes to analyze COVID-induced myocarditis by adding immune cells to their laboratory experiments. Competitors identified in this market include * Axol Bioscience Ltd. . * Cynata Therapeutics Limited * Evotec SE * Fate Therapeutics, Inc. . * FUJIFILM Cellular Dynamics, Inc. . * Ncardia * Pluricell Biotech * REPROCELL USA, Inc. . * Shenzhen Sanqi Biotechnology Co. . , GmbH. * Sumitomo Dainippon Pharma Co. . , GmbH. * Takara Bio, Inc. . * Thermo Fisher Scientific, Inc. . * ViaCyte, Inc. . Read the full report: https: // www. reportlinker. com / p05798831 /? utm_source = GNW I. . INTRODUCTION, METHODOLOGY & REPORT SCOPE I-1 II. SUMMARY II-1 1 . MARKET OVERVIEW II-1 Impact of Covid-19 and an Looming Global Recession II-1 Induced Pluripotent Stem Cells (iPSCs) Market Profits from Increased Use in Research for COVID-19 II-1 Studies Using iPSCs in COVID-19 Research II-2 Stem Cells, Areas of Application, and the Different Types: A Prelude II-3 Applications of Stem Cells II-4 Types of Stem Cells II-4 Induced Pluripotent Stem Cells (iPSC): An Introduction II-5 Production of iPSCs II-6 First & Second Generation Mouse iPSCs II-6 Human iPSCs II-7 Key Properties of iPSCs II-7 Transcription Factors Involved in the Generation of iPSCs II-7 Notable Research & Areas of Application for iPSCs II-8 Induced Pluripotent Stem Cells Market ( iPSC): Growth Prospects and Outlook II-9 Application of Drug Development for Substantial Growth II-11 Technical Breakthroughs, Advances in & Clinical Study n to promote the growth of the iPSC market II-11 North America dominates the global iPSC market II-12 Co. mpetition II-12 Current market activity II-13 Select innovation / progress II-16 2 . FOCUS ON SELECTED PLAYERS II-17 Axol Bioscience Ltd. . (United Kingdom) II-17 Cynata Therapeutics Limited (Australia) II-17 Evotec SE (Germany) II-17 Fate Therapeutics, Inc. . (USA) II-17 FUJIFILM Cellular Dynamics, Inc. . (USA) II-18 Ncardia (Belgium) II-18 Pluricell Biotech (Brazil) II-18 REPROCELL USA, Inc. . (USA) II-18 Sumitomo Dainippon Pharma Co. . , GmbH. (Japan) II-19 Takara Bio, Inc. . (Japan) II-19 Thermo Fisher Scientific, Inc. . (USA) II-20 ViaCyte, Inc. . (USA) II-20 3 . MARKET TRENDS & DRIVERS II-21 Effective Research Programs Are Critical to Introducing Advanced iPSC Treatments II-21 Induced Pluripotent Stem Cells: A Big Leap Into Therapeutic Applications II-21 Research Trends in Induced Pluripotent Stem Cell Space II-22 Figure 1: Worldwide publication of hESC – and hiPSC research papers for the period 2008-2010, 2011-2013 and 2014-2016 II-22 Annex 2: Number of original research papers published worldwide on hESC and iPSC (2014-2016) II-23 Concerns related to embryonic stem cells Shift Focus to iPSCs II-23 Regenerative Medicine: A Promising Use of iPSCs II-24 Induced Pluripotent: A Potential Competitor to hESCs? II-25 Exhibit 3: Global market size for regenerative medicine in billion US dollars for 2019, 2021, 2023 and 2025 II-27 Exhibit 4: Global market for regenerative stem cells & by product (in%) for 2019 II-27 exhibit 5: Global Regenerative Medicines Market by Category: Breakdown (in%) for Biomaterials, Stem Cell Therapies and Tissue Engineering for 2019 II-28 Pluripotent Stem Cells Are Relevant for Cardiovascular Regenerative Medicine II-28 Figure 6: Leading global causes of death: Number of deaths in millions &% Proportion of deaths by cause for 2017 II-30 Main causes of death for low and high-income countries II-30 Growing importance of iPSCs in the discovery of personalized medicines II-31 Sustained advances in genetics and subsequent growth in precision medicine Augur Well for the iPSC market II-33 Figure 7: Global market for precision medicine (in billions of US Dollars) for the years 2018, 2021 & 2024 II-34 Rising prevalence of chronic disorders supports the growth of the iPSC market II-34 Figure 8: Global cancer incidence: number of new cancer cases diagnosed for 2012, 2018 & 2040 II-35 Figure 9: Number of new cancer cases reported by cancer (in thousands) Type: 2018 II-36 Figure 10: Deaths by heart disease: Estimated percentage breakdown by cardiovascular disease, ischemic heart disease, stroke and other diseases II-37 Figure 11: Increasing Diabetes prevalence offers opportunities for iPSCs market: Number of adults (20- 79) with diabetes (in millions) by region for 2017 and 2045 II-38 Age demographics increase the global burden of chronic diseases and offer opportunities for the iPSC market II- 38 Figure 12: Expansion of the elderly population worldwide: Breakdown of the number of elderly people 65 years of age in millions by geographical region regions for 2019 and 2030 II-39 Growth in the number of genomics projects drives market growth II-39 Genomic initiatives in selected countries II-40 Figure 13: New gene editing tools encourage interest and investment in genetics and encourage lucrative growth opportunities for iPSCs: total VC financing (in million. USD) for genetics for the years 2014, 2015, 2016, 2017 and 2018 II-41 Start of numerous clinical studies in connection with iPSCs with a view to market growth II-41 Figure 14: Number of studies based on induced pluripotent stem cells according to selected conditions: As of 31. October 2020 II-43 Clinical study based on iPSCs for heart disease II-43-induced pluripotent stem cells for stroke treatment II-44? Off the shelf? Stem Cell Treatment for Cancer Enters Clinical Trial II-44 iPSCs for Hematological Diseases II-44 Market Advantages from Growing Funding for iPSCs-Related R&D Initiatives II-44 Annex 15: Funding for Stem Cell Research in the US (in millions. USD) for the years 2016 to 2021 II-46 Human iPSC Banks: An Overview of New Opportunities and Disadvantages II-46 Human iPSC Banks Worldwide: An Overview II-48 Cell Sources and Reprogramming Methods Used by Selected iPSC Banks II-49 Innovations , Research Studies & Advancements in iPSCs II-50 Major Breakthroughs in iPSC Research for Regenerative Medicine II-50 Researchers Develop Novel Oncogen-Free and Virus-Free iPSC Production Method II-51 Scientists Investigate Concerns About Genetic Mutations in iPSCs II-52 iPSCs Offer One Tremendous Potential for Transforming Research Efforts II-52 Researchers Point To Potential Use Of iPSCs To Develop Novel Cancer Vaccines II-54 Scientists Use Machine Learning To Improve Re-Adhesion Of iPSC Self-Organization II-54 STEMCELL Technologies Reveals mTeSR? Plus II-55 Challenges and Risks Associated with Pluripotent Stem Cells II-56 A Look at Problems Associated with Reprogramming Adult Cells in iPSCs II-57 A Note on Legal, Social, and Ethical Considerations with iPSCs II-58 4 . PERSPECTIVE OF THE GLOBAL MARKET II-59 Table 1: Worldwide current & future analysis for induced pluripotent stem cells (iPSC) by geographic region – USA, Canada, Japan, China, Europe, Asia-Pacific and other world markets – Independent analysis of annual sales in US thousands -Dollars for the years 2020 to 2027 II-59 Table 2: World 7-Year Perspective for Induced Pluripotent Stem Cells (iPSC) by Geographic Region – Percentage breakdown of value sales for USA, Canada, Japan, China, Europe, Asia-Pacific and other world markets for the years 2020 & 2027 II-60 Table 3: World current & future analysis for vascular cells by geographic region – USA, Canada, Japan, China, Europe, Asia-Pacific and other world markets – Independent analysis of annual sales in thousands of US Dollars for the years 2020 to 2027 II-61 Table 4: Worldwide 7-year perspective for vascular cells by geographic region – percentage breakdown d he sales for the USA, Canada, Japan, China, Euro ope, Asia-Pacific and the rest of the world for 2020 & 2027 II-62 Table 5: Current & future analysis for heart cells by geographic region – USA, Canada, Japan, China, Europe, Asia-Pacific and the rest of the world markets – Independent analysis of annual sales in thousands of US dollars for the years 2020 to 2027 II-63 Table 6: Worldwide 7-year perspective for heart cells by geographic region – Percentage breakdown of value sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of the World for 2020 & 2027 II-64 Table 7: World-current & future analysis for neural cells by geographic region – USA, Canada, Japan, China, Europe, Asia-Pacific and rest of world markets – Independent analysis of annual sales in thousands of US dollars for the years 2020 to 2027 II-65 Table 8: Worldwide 7-year perspective for neural cells by geographic region – proze ntual breakdown of value sales for the USA, Canada, Japan, China, Europe, Asia-Pacific and the rest of the world since 2020 & 2027 II-66 Table 9: Current & future analysis for liver cells by geographic region – USA, Canada, Japan, China , Europe, Asia-Pacific and Rest of the World – Independent Analysis of Annual Sales in Thousands of US Dollars for the Years 2020 to 2027 II-67 Table 10: World 7-Year Outlook for Liver Cells by Geographic Region – Percentage Breakdown of Value Sales for USA , Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 II-68 Table 11: Current & future analysis for immune cells by geographic region – USA, Canada, Japan, China, Europe, Asia-Pacific and other world markets – Independent analysis of annual sales in thousands of US dollars for the years 2020 to 2027 II-69 Table 12: Worldly 7-year perspective for immune cells by geographic region – Percentage breakdown of value sales for USA, Canada, Japan, China, Europe, Asia-Pacific and the rest of the world for years 2020 & 2027 II-70 Table 13: World current & future analysis for other cell types by geographic region – USA, Canada, Japan , China, Europe, Asia-Pacific and other world markets – Independent analysis of the annual sales in thousands of US dollars for the years 2020 to 2027 II-71 Table 14: Worldwide 7-year perspective for other cell types by geographic region – percentage breakdown of the Value sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 II-72 Table 15: Current & future analysis for cellular reprogramming by geographic region – USA, Canada, Japan, China, Europe, Asia-Pacific and other world markets – Independent analysis of annual sales in thousands of US dollars for the years 2020 to 2027 II-73 Table 16: Worldwide 7-year perspective for r cellular reprogramming by geographic region – percentage breakdown of value sales for USA, Canada, Japan, China, Europe, Asia-Pacific and rest of the world for years 2020 & 2027 II-74 Table 17: World current & future analysis for cell culture according to Geographic regions – USA, Canada, Japan, China, Europe, Asia-Pacific and the rest of the world markets – Independent analysis of annual sales in thousands of US dollars for the years 2020 to 2027 II-75 Table 18: Worldwide 7-year perspective for the Cell Culture by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of the World for 2020 & 2027 II-76 Table 19: World-Current & Future Analysis for Cell Differentiation by Geographic Region – USA , Canada, Japan, China, Europe, Asia-Pacific and the rest of the world markets – Independent analysis of annual sales in thousands of US dollars for the years 2020 to 2027 II-77 Table 20: Worldwide 7-year perspective for cell differentiation by geographic region – percentage breakdown of value sales for USA, Canada, Japan, China, Europe, Asia-Pacific and rest of the world for the years 2020 & 2027 II -78 Table 21: Current & future analysis for cell analysis by geographic region – USA, Canada, Japan, China, Europe, Asia-Pacific and rest of world markets – Independent analysis of annual sales in thousands of US dollars for the years 2020 to 2027 II -79 Table 22: Worldwide 7-Year Perspective for Cell Analysis by Geographic Region – Percentage Breakdown of Value Sales for the USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of the World for 2020 & 2027 II-80 Table 23: Current & Future Analysis for Cellular Technology by Geographic Region – USA, Canada, Japan, China, Europe, Asia Pacific and Rest of the World – Independent Analysis of Annual Sales it in thousands of US dollars for the years 2020 to 2027 II-81 Table 24: Worldwide 7-year perspective for cellular construction by geographic region – percentage breakdown of value sales for the USA, Canada, Japan, China, Europe, Asia-Pacific and rest of the world for 2020 & 2027 II-82 Table 25: World current & future analysis for other research methods by geographic region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent analysis of annual sales in thousands of US dollars for the years 2020 to 2027 II-83 Table 26: 7-year world perspective for other research methods by geographic region – percentage breakdown of value sales for USA, Canada, Japan, China, Europe, Asia-Pacific and the rest of the World for Years 2020 & 2027 II-84 Table 27: World Current & Future Analysis for Drug Development & Toxicology Tests by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Sales in Thousands of US Dollars for the Years 2020 to 2027 II-85 Table 28: Worldwide 7-Year Perspective for Drug Development & Toxicology Tests by Geo Graphic Region – Percentage Breakdown of Value Sales for the United States, Canada, Japan, China, Europe, Asia Pacific, and the Rest of the World for 2020 & 2027 II-86 Table 29: Current & Future Analysis for Academic Research by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Analysis of Annual Revenue in Thousands of US Dollars for the Years 2020 to 2027 II-87 Table 30: Secular 7-Year Perspective for Academic Research by Geographic Region – Percentage breakdown of value sales for the United States, Canada, Japan, China, Europe, Asia-Pacific and the rest of the world for years 2 020 & 2027 II-88 Table 31: Worldwide current & future analysis for regenerative medicine by geographic region – USA, Canada, Japan, China, Europe, Asia-Pacific and other world markets – Independent analysis of annual sales in thousands of US dollars for the years 2020 to 2027 II-89 Table 32: Secular 7-Year Perspective for Regenerative Medicine by Geographic Region – Percentage Breakdown of Value Sales for United States, Canada, Japan, China, Europe, Asia Pacific, and Rest of the World for the Years 2020 & 2027 II-90 Table 33: Current & future analysis for other applications by geographic region – USA, Canada, Japan, China, Europe, Asia-Pacific and other world markets – Independent analysis of annual sales in thousands of US dollars for the years 2020 until 2027 II-91 Table 34: Worldwide 7-year perspective for other applications according to geographical features Region – Percentage breakdown of value sales fe for the USA, Canada, Japan, China, Europe, Asia-Pacific and the rest of the world for 2020 & 2027 II-92 III. MARKET ANALYSIS III-1 GEOGRAPHICAL MARKET ANALYSIS III-1 UNITED STATES III-1 Table 35: USA Current & future analysis for induced pluripotent stem cells (iPSC) by cell type – vascular cells, heart cells, neuron cells, liver cells, immune cells and other cell types – independent analysis of annual turnover Thousands of US Dollars for the Years 2020 to 2027 III-1 Table 36: 7-Year Outlook for the US for Induced Pluripotent Stem Cells (iPSC) by Cell Type – Percentage Breakdown of Value Sales for Vascular Cells, Heart Cells, Neural Cells, Liver Cells, Immune Cells and other cell types for 2020 & 2027 III-2 Table 37: USA Current & future analysis for induced pluripotent stem cells (iPSC) by research method – cellular reprogramming, cell culture, cell differentiation, cell analysis, cellular engineering and other research methods – independent analysis of annual sales in thousands US dollars for the years 2020 to 2027 III -3 Table 38: US 7-Year Outlook for Induced Pluripotent Stem Cells (iPSC) by Research Method – Percentage Breakdown of Value Sales for Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cell Technology and Other Research Methods for 2020 & 2027 III-4 Table 39: USA Current & Future Analysis for Induced Pluripotent Stem Cells (iPSC) by Application – Drug Development & Toxicology Tests, Academic Research, Regenerative Medicine, and Other Applications – Independent Analysis of Annual Sales in Thousands of US Dollars for 2020-2027 III-5 Table 40: U.S. 7 Year Perspective on Induced Pluripotent Stem Cells (iPSC) by Application – Percentage Breakdown of Value Sales for Drug Development & Toxicological Testing, Academic Research, Regenerative Medicine, and Other Uses for 2020 & 2027 III-6 CANADA III- 7 table le 41: Canada Current & future analysis for induced pluripotent stem cells (iPSC) by cell type – vascular cells, heart cells, neuronal cells, liver cells, immune cells and other cell types – Independent analysis of annual sales in thousands of US dollars for the years 2020 to 2027 III- 7 Table 42: Canada’s 7-year perspective for induced pluripotent stem cells (iPSC) by cell type – percentage breakdown of value sales for vascular cells, heart cells, neuronal cells, liver cells, immune cells and other cell types for the years 2020 & 2027 III-8 Table 43: Canada Current & Future Analysis for Induced Pluripotent Stem Cells (iPSC) by Research Method – Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods – Independent Analysis of Annual Sales in US Dollars Thousands for the Years 2020 to 2027 III-9 Table 44: Canada’s 7-Year Perspective for Induced Pluripotent Strains ellen (iPSC) by Research Method – Percentage Breakdown of Value Sales for Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods for 2020 & 2027 III-10 Table 45: Canada Current & Future Analysis for Induced Pluripotent Stem Cells (iPSC) According to Application – Drug Development & Toxicological Testing, Academic Research, Regenerative Medicine, and Other Applications – Independent Analysis of Annual Sales in Thousands of Dollars for 2020-2027 III-11 Table 46: Canada 7-Year Perspective for Induced Pluripotent Stem Cells (iPSC ) by Application – Percentage Breakdown of Value Sales for Drug Development & Toxicological Testing, Academic Research, Regenerative Medicine and Other Applications for 2020 & 2027 III-12 JAPAN III-13 Table 47: Japan Current & Future Analysis for Induced Pluripotent Stem Cells (iPSC) by Cell Type – Vascular Cells, Heart Cells, Neuro Cells, Liver Cells, Immune Cells and Other Cell Types – Independent Analysis of Annual Sales in Thousands of US Dollars for the Years 2020 to 2027 III-13 Table 48: Japanese 7-Year Perspective for Induced Pluripotent Stem Cells (iPSC) by Cell Type – Percentage Breakdown of Value Sales for Vascular Cells, Heart Cells, Neural Cells, Liver Cells, Immune Cells and Other Cell Types for 2020 & 2027 III-14 Table 49: Japan Current & Future Analysis for Induced Pluripotent Stem Cells (iPSC ) by research method – cellular reprogramming, cell culture, cell differentiation, cell analysis, cellular technology and other research methods – independent analysis of annual sales in thousands of US dollars for the years 2020 to 2027 III-15 Table 50: Japan 7-year perspective for induced pluripotent stem cells ( iPSC) by research method – percentage breakdown d he value sales for cellular reprogramming, cell culture, cell differentiation, cell analysis, cellular engineering and other research methodologies for 2020 & 2027 III-16 Table 51: Japan Current & Future Analysis for Induced Pluripotent Stem Cells (iPSC) by Application – Drug Development & Toxicology Tests, Academic Research , Regenerative Medicine and Other Applications – Independent Analysis of Annual Sales in Thousands of US Dollars for the Years 2020 to 2027 III-17 Table 52: Japan’s 7-Year Outlook for Induced Pluripotent Stem Cells (iPSC) by Application – Percentage Breakdown of Value Sales for the Drug development & Toxicology Testing, Academic Research, Regenerative Medicine and other applications for 2020 & 2027 III-18 CHINA III-19 Table 53: China Current & future analysis for induced pluripotent stem cells (iPSC) by cell type – vascular cells, heart cells, neuron All cells, liver cells, immune cells and other cell types – Independent analysis of annual sales in US $ T. Housand for the Years 2020 to 2027 III-19 Table 54: China’s 7-Year Perspective for Induced Pluripotent Stem Cells (iPSC) by Cell Type – Percentage Breakdown of Value Sales for Vascular Cells, Heart Cells, Neuronal Cells, Liver Cells, Immune Cells and Other Cell Types for the Years 2020 & 2027 III-20 Table 55: China Current & Future Analysis for Induced Pluripotent Stem Cells (iPSC) by Research Method – Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cell Engineering and Other Research Methods – Independent analysis of annual sales in thousands of US dollars for the Years 2020 to 2027 III-21 Table 56: China 7-Year Perspective for Induced Pluripotent Stem Cells (iPSC) by Research Method – Percentage breakdown of the value turnover for cellular reprogramming, cell culture, cell differentiation, cell analysis, cellular engineering and other research methods for the years 2020 & 2027 III-22 Tabel le 57: C. hina Current & Future Analysis for Induced Pluripotent Stem Cells (iPSC) by Application – Drug Development & Toxicology Tests, Academic Research, Regenerative Medicine and Other Applications – Independent Analysis of Annual Sales in Thousands of US Dollars for the Years 2020 to 2027 III-23 Table 58: China 7 Year Prospect for Induced Pluripotent Stem Cells (iPSC) by Application – Percentage Breakdown of Value Sales for Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine and Other Uses for 2020 & 2027 III-24 EUROPA III- 25 Table 59: Europe Current & Future Analysis for Induced Pluripotent Stem Cells (iPSC) by Geographic Region – Markets in France, Germany, Italy, Great Britain and Rest of Europe – Independent Analysis of Annual Sales in Thousands of US Dollars for the Years 2020 to 2027 III- 25 Table 60 : 7 year perspe Ctive Europe for Induced Pluripotent Stem Cells (iPSC) according to geographical features Region – Percentage breakdown of value sales for the markets France, Germany, Italy, Great Britain and the rest of Europe for the years 2020 & 2027 III-26 Table 61: Current & future analysis for induced Pluripotent stem cells (iPSC) by cell type – vascular cells, heart cells, neural cells, liver cells, immune cells and other cell types – independent analysis of annual sales in thousands of US dollars for the years 2020 to 2027 III-27 Table 62: Europe 7-year perspective for induced pluripotent stem cells (iPSC) by cell type – percentage breakdown of value sales for vascular cells, heart cells, neuronal cells, liver cells, immune cells and other cell types for the years 2020 & 2027 III-28 Table 63: Europe Current & future analysis for induced pluripotent stem Cell (iPSC) according to research method – Cellular Repr oprogramming, cell culture, cell differentiation, cell analysis, cellular technology and other research methods – Independent Analysis of annual sales in thousands of US dollars for the years 2020 to 2027 III-29 Table 64: 7-year perspective for Europe for induced pluripotent stem cells (iPSC) by research method – Percentage Breakdown of Value Sales for Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering and Other Research Methods for 2020 & 2027 III-30 Table 65: Europe Current & Future Analysis for Induced Pluripotent Stem Cells (iPSC) by Application – Drug Development & Toxicology Tests, Academic Research, Regenerative Medicine and Other Applications – Independent Analysis of Annual Sales in Thousands of US Dollars for the Years 2020 to 2027 III-31 Table 66: 7-Year Outlook for Europe for Induced Pluripotent Stem Cells (iPSC) by Application – Percentage Breakdown of drug development value sales & Toxicological Testing, Academic Research, Regenerative Medicine and other uses for 2020 & 2027 III-32 FRANCE III-33 Table 67: France Current & Future Analysis for Induced Pluripotent Stem Cells (iPSC) by Cell Type – Vascular Cells , Heart cells, neural cells, liver cells, immune cells and other cell types – Independent analysis of annual sales in thousands of US dollars for the years 2020 to 2027 III-33 Table 68: France’s 7-year perspective for induced pluripotent stem cells (iPSC) by cell type – Percentage breakdown of the turnover for vascular cells, heart cells, neuronal cells, liver cells, immune cells and other cell types for the years 2020 & 2027 III-34 Table 69: France Current & future analysis for induced pluripotent stem cells (iPSC) according to research method – cell reprogramming, cell culture, cell differentiation , Zella Analysis, Cellular Technology and Other Research Methods – Independent Analysis of Annual Sales in Thousands of US Dollars for the Years 2020 to 2027 III-35 Table 70: Fra 7-Year Perspective for Induced Pluripotent Stem Cells (iPSC) by Research Method – Percentage Breakdown of Value Sales for Cellular Reprogramming, cell culture, cell differentiation, cell analysis, cell engineering and other research methods for 2020 & 2027 III-36 Table 71: France Current & Future Analysis for Induced Pluripotent Stem Cells (iPSC) by Application – Drug Development, & Toxicology Tests, Academic Research, Regenerative Medicine and Other applications – Independent analysis of annual sales in thousands of US dollars for the years 2020 to 2027 III -37 Table 72: France’s 7-year perspective for induced pluripotent stem cells (iPSC) by application – percentage breakdown of value sales for drug development CSS EANDCHAR toxicology tests, academic research, regenerative medicine and other applications for 2020 & 2027 III-38 GERMANY III-39 Table 73: Germany Current & Future Ana lysis for induced pluripotent stem cells (iPSC) by cell type – vascular cells, heart cells, neuronal cells, Liver cells, immune cells and other cell types – independent analysis of annual sales in thousands of US dollars for the years 2020 to 2027 III-39 Table 74: Germany 7-year perspective for induced pluripotent stem cells (iPSC) by cell type – percentage breakdown of sales for Vascular cells, heart cells, neuronal cells, liver cells, immune cells and other cell types for the years 2020 & 2027 III-40 Table 75: Germany Current & future analysis for induced pluripotent stem cells (iPSC) according to research method – cellular reprogramming, cell culture, cell differentiation, cell analysis, cellular technology and other research met testes – Independent Analysis of Annual Sales in US Dollars Thousands for 2020 to 2027 III-41 Please contact our Customer Service Center for the full table of contents. Read the full report: https: // www. reportlinker. com / p05798831 /? utm_source = GNW About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you can get all of the market research you need – instantly in one place. __________________________ CONTACT: Clare: clare @ reportlinker. com US: (339) -368-6001 Intl: 1 339-368-6001

The report « Prestressed Concrete Strands Insights, Global Market Insight 2020, Analysis, and Forecast to 2025, By Manufacturer, Region, Technology, Application » has been added to ResearchAndMarkets. com offer.

The reality TV star – real name Colin Newell – also appeared regularly on Arsenal’s fan station AFTV.

Motive Capital Corp (the « Company ») announced today that it has filed a registration statement on Form S-1 (the « Registration Statement ») with the Securities and Exchange Commission (the « SEC ») in relation to the proposed initial has public offer from 30. 000. 000 units priced at $ 10. 00 per share consisting of Class A common shares of the Company and one third of a redeemable warrant. Each entire warrant entitles the holder to one common share of the company priced at $ 11. 50 per share. The company has requested to list its shares on the New York Stock Exchange under the symbol « MOTV ». U. . « 

Key companies falling under the Industrial Gases market research report include Mohsin Haider Darwish LLC, Bhuruka Gases Ltd. , Bristol Gases, Dubai Industrial Gases, Air Products, Southern Company Gas, Concorde-Corodex Group, Ellenbarrie Industrial Gases Ltd. . , Air liquid, universal industrial gases, Messer Group, BASF, Linde, Gulf Cryo, Matheson Tri-Gas, other players. Pune, Nov. . Feb 25, 2020 (GLOBE NEWSWIRE) – The global industrial gases market size is expected to show remarkable growth in the forecast years due to increasing global demand from the oil and gas industry. Industrial gases are used in various applications, e.g.. B.. in foods like &, oil and gas, petrochemicals, healthcare, chemicals and others. According to a recent report from Fortune Business Insights entitled, Industrial Gases Market Size, Share, and Industry Analysis, By Gas Type (Oxygen, Nitrogen, Carbon Dioxide, Hydrogen, Argon, and Others), By Application (Packaging, Coolant, Carbonation), Cryogen, Cutting Of & welding, laboratory, air separation and others), by end user (metallurgy, healthcare, chemistry, food, & beverages, oil, & gas, electricity, pulp and paper, electronics, water treatment, mining and others) and regional forecast, 2020-2027 “the market value was 95 USD. 71 billion in 2019 and is projected to rise at a CAGR of 6. 0%. It would reach USD 149. 33 billion by the end of 2027. Click here for the short term and long term impact of COVID-19 on this market. Please visit: https: // www. Fortune Business Insights. com / Industry Reports / Industrial Gases-Market-101728 The current COVID-19 pandemic has brought most companies worldwide to a standstill. Import and export transportation has come to a standstill, which continues to affect international companies. The fact that we are not aware of the continuity of this lockdown period not only creates chaos among people worldwide, but also affects the global economy as a whole. However, we hope soon to overcome this obstacle with the help of government support. At Fortune Business Insights, we provide detailed analytical reports on various markets affected by the COVID-19 pandemic and their future prospects. These reports are a prognostic study of the current situation on several exchanges and what steps can be adjusted to achieve the greatest possible benefit and thus bring stable revenue to these markets for the foreseeable future. What are the goals of the report? The report is based on a 360-degree analysis of the market, its key parameters namely market restraints, drivers, challenges, opportunities and future prospects. It also highlights the market segmentation in detail and lists the names of the leading segment with the base and forecast figures. In addition, the important industry developments, interesting findings and current trends on the industrial gases market are discussed. Please visit the company’s website for more information on the report. Get sample PDF brochure: https: // www. Fortune Business Insights. com / inquiry / request-sample-pdf / industriegase-markt-101728 Drivers & Restrictions – Growing Health Sector Demand for Market Impetus An increase in crude oil prices and an increase in refining needs have demanded, particularly from the oil and gas industry. In addition, they are also used for various purposes, such as:. B.. for wound pipes, cooling and inerting of pipes, drilling, leak testing, maintenance, coil base in pipe construction and others. Such factors promote the growth of the industrial gases market. In addition, the expansion of the & beverage industry in the health and food sectors is contributing to the growth of the market. On the contrary, the current outbreak of the COVID-19 pandemic and its impact on various industries are likely to hamper the market in the years to come. This, combined with the strict regulations governing the storage, manufacture and distribution of industrial gases, may hamper the growth of the market in the years to come. However, an increase in industrialization and urbanization as well as growing consumer demand from the manufacturing and manufacturing industries should create lucrative growth opportunities for the market in the long term. Segment: Oxygen segment will continue to dominate due to increasing demand from the pharmaceutical industry Due to the segmentation by gas type, the oxygen segment achieved 28. Market share of 9% industrial gases in 2019. This is due to the extensive oxygen consumption and high demand from various sectors such as pulp and paper, chemicals, pharmaceuticals and petroleum. However, the carbon dioxide segment will also see remarkable growth due to its significant uses as a raw material in products such as meat, fruits and vegetables, poultry and others. Talk to the analyst: https: // www. Fortune Business Insights. com / inquiry / speak-to-analyst / industrial gases-market-101728 regional analysis-Asia-Pacific dominated by rapid industrialization & urbanization Due to the regional segmentation, the market is dominated by Asia-Pacific with a turnover of USD 31. 05 billion in 2019. Factors attributed to the growth of this region include rapid urbanization and industrialization, as well as an increase in investment by various nations such as India, China, Indonesia, Japan and others in sustainable energy development. On the other hand, North America ranks second. With the & gas industry’s increasing application in the chemical, healthcare and oil sectors, the company is expected to generate significant revenues in the years to come. Competitive landscape – Linde achieves maximum share that can be attributed to an increase in industrial investments The global market is dominated by Linde due to its high investments in the pharmaceutical and healthcare sectors. In addition, the company is investing heavily in improving the economic scenario. The company also supplies its products to the growing number of manufacturing and metalworking industries as well as the & food, chemical and oil & gas industries. The other actors participate in mergers and acquisitions, joint ventures, contracts and agreements, various cooperation strategies and others to gain a competitive advantage in the market. Key Market Developments Include: June 2019 – Exxon Mobil Asia Pacific Pvt. GmbH. and Linde have made billions of agreements to expand their geographic reach in Singapore. This project includes the construction, development and operation of four additional gasifiers, an air separation plant with a capacity of 1200 tons per day (TPD) and sulfur recovery plants as well as the processing units for downstream gas from Linde. Key companies listed in the Industrial Gases Market are * Mohsin Haider Darwish LLC * Bhuruka Gases Ltd. * Bristol Gases * Dubai Industrial Gases * Air Products * Southern Company Gas * Concorde-Corodex Group * Ellenbarrie Industrial Gases Ltd. . * Air liquid * Universal industrial gases * Messer Group * BASF * Linde * Golf-Kryo * Matheson Tri-Gas * Other players Quick purchase – market research report for industrial gases: https: // www. Fortune Business Insights. com / checkout-page / 101728 Detailed Table of Contents * Introduction * Research Scope * Market Segmentation * Research Methodology * Definitions and Assumptions * Summary * Market Dynamics * Market Drivers * Market Restrictions * Market Opportunities * Key Findings * Key New Trends – For Key Countries * Latest Technological Advancement * Regulatory Landscape * Industries -SWOT Analysis * Porter’s Five Forces Analysis * Qualitative Analysis – Impact of COVID-19 * Impact of COVID-19 on the Industrial Gases Market * Government Steps to Overcome the Impact * Key Developments in the Industry in Response to COVID-19 * Possible Opportunities and challenges due to the COVID-19 outbreak * Global market analysis for industrial gases (in billion. USD), Findings and Forecasts, 2016-2027 * Key Findings / Summary * Market Analysis, Findings, and Forecast – By Gas Type * Oxygen * Nitrogen * Carbon Dioxide * Hydrogen * Argon * Other * Market Analysis, Findings and Forecasts – By Application * Packaging * Refrigerant * Carbonation * Cryogenic * Air Separation * Cutting & Welding * Laboratory * Other * Market Analysis, Insights, and Forecasts – By End User * Metallurgy * Healthcare * Chemical * Food & Beverage * Oil & Gas * Electricity * Pulp and Paper * Electronics * Water Treatment * Mining * Other * Market Analysis, Insights, and Forecasts – By Regions * North America * Latin America * Europe * Asia Pacific * Middle East and Africa Table of Contents continued. . Get your bespoke research report: https: // www. Fortune Business Insights. com / inquiry / customization / industriegase-market-101728 Take a look at Related Research: 3D Printing Gases Market Size, Share & Industry Analysis, By Type (nitrogen, argon, gas mixtures), by technology (stereolithography, laser sintering), poly-jet Technology, other), by storage (cylinder & packaged, commercial liquid, tonnage), by application (healthcare, consumer goods, design and manufacture, other) and regional forecast, 2020-2027 switching market size, share of & industry analysis, by insulation (gas, air, oil , Vacuum), by voltage (low, medium, high), by end-user (T&D utility, industrial, commercial, & residential), by installation (indoor, outdoor), and regional forecast 2019 -2026Pad-Mounted Switchgear Market Size, Share & Industry Analysis, according to type (air-insulated, gas-insulated, solid dielectric, other), according to nominal voltage (up to 15 kV, 15-25 kV, 25-38 kV), according to application ( Residential, Industry, Commercia l) Other and regional forecast, market size, share and global trend for low-voltage switchgear 2019-2026 by product (fixed installation, plug-in, pull-out unit), by nominal voltage (less than 250 V, 250-750 V, 751-1000 V), after installation (indoors, outdoors), according to application (substation, distribution, power factor correction, sub-distribution, motor control) and geographic forecast up to 2026 About us: Fortune Business Insights ™ offers competent company analyzes and precise data and helps companies of all sizes to meet timely decisions. We put together innovative solutions for our customers and support them in mastering challenges that are different for their company. It is our goal to provide our customers with comprehensive market information and to give a detailed overview of the market in which they operate. Our reports contain a unique blend of concrete insight and qualitative analysis to help companies achieve sustainable growth. Our team of seasoned analysts and consultants use industry leading research tools and techniques to produce comprehensive market studies with relevant data. At Fortune Business Insights ™, we want to highlight the most lucrative growth opportunities for our customers. We therefore offer recommendations that will make it easier for you to navigate through technological and market-related changes. Our consulting services are designed to help companies identify hidden opportunities and understand the current competitive challenges. Contact us: Fortune Business Insights ™ Pvt. GmbH. 308, Supreme Headquarters, Poll No.. 36, Baner, Pune-Bangalore Highway, Pune – 411045, Maharashtra, India. Phone: USA: 1-424-253-0390 UK: 44-2071-939123 APAC: 91-744-740-1245 Email: sales @ Fortunebusinessinsights. com Fortune Business Insights ™ LinkedIn | Twitter | Blogs Read the press release: https: // www. Fortune Business Insights. com / press release / industrial-gases-market-10061

Hyderabad (Telangana) [India], 25. November (ANI): Telangana Rashtra Samithi (TRS) party believes in crucial politics, not divisive politics, and people should think about what the BJP and Congress have been doing over the years, Kalvakuntla Taraka Rama Rao, Minister of City Administration and Development and TRS chairman told ANI on Wednesday.

(Bloomberg) – The U. . K. . Government plans to issue a record 485. £ 5 billion ($ 648 billion) in bonds this fiscal year to fight the economic damage caused by the coronavirus pandemic. The Debt Management Office announced Wednesday December-March additional loans of £ 92 billion. The annual figure is more than double what it was during the height of the global financial crisis and compared to analyst estimates of 482. £ 8 billion according to a Bloomberg survey of 12 primary traders. The surge in borrowing reflects the rising cost of widespread lockdowns that closed businesses, kept workers at home, and pushed the economy into its deepest recession in three centuries. It will also add £ 2 trillion in government debt and risk burdening the market. « The U. K. . The economy currently has a large amount of life support, ”said Liam O’Donnell, money manager at Aberdeen Standard Investments, prior to the announcement. “A modest increase in yield is fine, everything else is practically a short circuit to activity while the economy is still affected by the crisis. « For now, the surge in debt sales has not increased the government’s borrowing costs, largely thanks to the Bank of England’s bond purchase program. The return for 10 year old gilts fell by one basis point to 0. 32% after more than halving this year as the central bank sucked up the issue. The BOE expanded its so-called quantitative easing program this month by £ 150 billion to £ 895 billion. Inflation meter It has been shown to be highly effective with a vaccine developed by the University of Oxford and AstraZeneca Plc – along with those from Pfizer Inc and Moderna Inc. . – and a Brexit trade deal is approaching, and the economic outlook for 2021 could be positive. The nation’s deficit grew less-than-expected in October, data showed last week. The DM0 is supposed to sell 393. £ 6 billion in bonds in fiscal year ended Jan.. November. 6 billion pounds more than originally planned, it said. £ 228 billion was raised during the height of the financial crisis in 2009-2010. Meanwhile, the Bureau of Budgetary Responsibility said the U. . K. . would align the malignant inflation indicator methodology for the retail price index with the CPIH measurement in February 2030. The move to the new benchmark, which has seen steadily slower price increases since 2010, threatened to undermine future returns on inflation-linked bonds. The government said it would not offer any compensation to the holders of the securities. The 10-year breakeven point rose 9 basis points to 3. 09%, the biggest increase since 2017. Still, « long linkers should begin to see the benefit of re-asking, » said Adam Dent, U. . K. . Rate strategist at Banco Santander SA. There is now « certainty » what « RPI » will mean in a given year. ”(Adds the 2009-2010 debt sales number in the eighth paragraph) You can find more articles like this at bloomberg. comSubscribe now to stay one step ahead with the most trusted business news source. © 2020 Bloomberg L. . P. .

Durable, Goods, Manufacturing